AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)

PHASE4CompletedINTERVENTIONAL
Enrollment

562

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

April 26, 2019

Study Completion Date

June 1, 2019

Conditions
Post-Operative Atrial Fibrillation
Interventions
DEVICE

AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems

DRUG

Anticoagulation Therapy

Anticoagulation Therapy- Standard of Care at the discretion of the Investigator.

Trial Locations (22)

10016

NYU Langone Medical Center, New York

10025

Mount Sinai -St. Luke's, New York

10029

Icahn School of Medicine at Mount Sinai, New York

17101

PinnacleHealth Hospitals, Harrisburg

21201

University of Maryland, Baltimore

22601

Valley Health System, Winchester

30308

Emory St Joseph Hospital, Atlanta

32806

Orlando Health Heart Institute, Orlando

37660

Wellmont CVA Heart Institute, Kingsport

38120

Cardiovascular Surgery Clinic, Memphis

38801

Cardiology Associates Research, Tupelo

45219

The Christ Hospital -Linder Research Center, Cincinnati

45220

Tri-Health, Cincinnati

46237

St Francis Heart Hospital, Indianapolis

46290

St. Vincent Heart Center, Inc., Indianapolis

54401

Aspirus Wausau Hospital, Wausau

55102

United Heart & Vascular Clinic, Saint Paul

66160

University of Kansas Hospital, Kansas City

92123

Sharp Memorial Hospital, San Diego

94304

Stanford University, Stanford

97239

Oregon Health and Science University, Portland

98122

Swedish Medical Center/Cherry Hill Campus, Seattle

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AtriCure, Inc.

INDUSTRY

NCT02701062 - AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS) | Biotech Hunter | Biotech Hunter